Blucora is a provider of technology-enabled financial solutions. The company has two reportable segments: Wealth Management and Tax Preparation. The Wealth Management business consists of the operations of Avantax Wealth Management, which provides tax-focused wealth management solutions for financial advisors, tax preparers, certified public accounting firms, and their clients and is a tax-focused independent broker-dealer. The Tax Preparation business consists of the operations of TaxAct, Inc., which provides digital do-it-yourself tax preparation solutions for consumers, small business owners and tax personnel through its website www.TaxAct.com.

Everbridge is a software company that provides enterprise software applications that automate and accelerate organizations' operational response to events in order to keep people safe and businesses running. Through its Critical Event Management platform, the company delivers applications that provide organizations with the ability to assess threats, locate people, automate actions, monitor incident response, and deliver contextual communications in any volume, in near-real time. The company's applications include mass notification, safety connection, incident management, information technology alerting, visual command center, public warning, community engagement , crisis management, and secure messaging.

HealthEquity provides technology-enabled services platforms that enable consumers to make healthcare saving and spending decisions. The company's platform provides an ecosystem where consumers can access their tax-advantaged healthcare savings, compare treatment options and pricing, evaluate and pay healthcare bills, receive personalized benefit and clinical information, earn wellness incentives, and make educated investment choices to grow their tax-advantaged healthcare savings. The company's products and services include healthcare saving and spending platform; health savings accounts; investment platform and advisory services, reimbursement arrangements; and HealthEquity retirement.

Hemisphere Media Group is a holding company. Through its subsidiaries, the company is a Spanish-language media company serving the United States Hispanic and Latin American markets with broadcast and cable television networks and digital content platforms. The company's portfolio includes: Cine Latino, Inc., a Spanish-language cable movie network with subscribers across the United States, Latin America and Canada; Televicentro of Puerto Rico, LLC, a broadcast television network and television content producer in Puerto Rico; and Snap Global, LLC, a distributor of content to broadcast and cable television networks and OTT and SVOD platforms in Latin America.

Matador Resources is an independent energy company engaged in the exploration, development, production and acquisition of oil and natural gas resources in the United States, with a focus on oil and natural gas shale and other unconventional plays. The company's operations are focused on the oil and liquids-rich portion of the Wolfcamp and Bone Spring plays in the Delaware Basin in Southeast New Mexico and West Texas. The company also operates in the Eagle Ford shale play in South Texas and the Haynesville shale and Cotton Valley plays in Northwest Louisiana. Also, the company conducts midstream operations, through its midstream joint venture, San Mateo Midstream, LLC together with San Mateo Midstream II, LLC.

Net 1 UEPS Technologies provides financial technology, products and services. The company has developed and owns most of its payment technologies, and where possible, utilizes this technology to provide financial and services to its customers by including them into the formal financial system. The company's primary payment technology is called the Universal Electronic Payment System (UEPS), and its EMV interoperable derivative, UEPS/EMV, utilizes a form of distributed ledger technology, providing decentralized and biometrically secure smart cards that operate in real-time but both off-line and on-line. The company's financial inclusion products and services are delivered through its UEPS-based core banking system.

Nevro is a medical device company that has developed and commercialized the Senza? spinal cord stimulation, a neuromodulation platform for the treatment of chronic pain. The Senza system is approved to create electrical impulses from two Hz to 10,000 Hz, including the company's proprietary HF10 therapy, which allows for pain relief without paresthesia. Senza is consisted of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger. These components enable physicians to implant the leads and the IPG, and patients to operate the system.

Ocular Therapeutix is a biopharmaceutical company focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its proprietary, bioresorbable hydrogel platform technology. The company has product candidates in clinical and preclinical development to treat post-surgical ocular pain and inflammation, allergic conjunctivitis, dry eye disease, among other conditions. The company's drug application, DEXTENZA? (dexamethasone ophthalmic insert) 0.4mg is for intracanalicular use for the treatment of ocular pain following ophthalmic surgery. The company is also assessing the potential use of its hydrogel platform technology in other areas of the body.

PetIQ is a holding company. Through its subsidiaries, the company is a pet medication and wellness company providing veterinary products and services. The company's Rx pet medications include heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics and other specialty medications, all of which require a prescription from a veterinarian. The OTC medications the company sells are primarily comprised of flea and tick control products, which are available in multiple forms that consumers choose between, such as spot on (topical) treatments, chewables, and collars. The company's health and wellness products include treats and other pet products such as dental treats and nutritional supplements.

Radius Health is a biopharmaceutical company focused on developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company's commercial product, TYMLOSTM (abaloparatide) injection is designed for the treatment of postmenopausal women with osteoporosis at high risk for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The company is developing an abaloparatide transdermal patch for potential use in the treatment of postmenopausal women with osteoporosis. The company is also developing its Elacestrant, a selective estrogen receptor degrader, for potential use in the treatment of hormone receptor-positive breast cancer.

Safehold is a holding company. Through its subsidiaries, the company operates its business through one segment by acquiring, managing and capitalizing ground leases. Ground leases generally represent the ownership of land underlying commercial real estate properties, which are leased on a long-term basis (base terms are 30 to 99 years, often with tenant renewal options) by the land owner to a tenant that owns and operates the building on top of the land, or what the company refer to as a Safehold?.

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of diseases. The company is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophies, Mucopolysaccharidosis type IIIA and other neuromuscular and central nervous system. The company's commercial product, EXONDYS 51? (eteplirsen) Injection is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

Six Flags Entertainment is a theme park operator and also an operator of waterparks. The company's parks provide a selection of thrill rides, water attractions, themed areas, concerts and shows, restaurants, game venues and retail outlets. The company holds licenses for theme park usage of certain Warner Bros. and DC Comics characters throughout the U.S. (except the Las Vegas metropolitan area), Canada, Mexico and other countries. The company's licenses include the right to sell merchandise featuring the characters at the parks, and to use the characters in its advertising, as walk-around characters and in theming for rides, attractions and retail outlets.

Synalloy is engaged in the following segments, the Metals segment and the Specialty Chemicals segment. The Metals segment manufactures welded pipe and tube, primarily from stainless steel, duplex, and nickel alloys; manufactures fiberglass and steel storage tanks; distributes hot finish, seamless, carbon steel pipe and tubing; and manufactures ornamental stainless steel tubing. The Specialty Chemicals segment manufactures lubricants, surfactants, defoamers, reaction intermediaries, and sulfated fats and oils, and provides chemical tolling manufacturing resources to global and regional companies and contracts with other chemical companies to manufacture certain pre-defined products.

TPI Composites is a holding company that conducts all of its business operations through its direct and indirect subsidiaries. The company is engaged as an independent manufacturer of composite wind blades for the wind energy market. The company is a supplier to its original equipment manufacturers customers in the manufacture of wind blades and related molding and assembly systems. The company uses its composite technology to supply composite products to the transportation market. The company's tooling solutions include wind blade patterns, molding and assembly systems, including modular tooling techniques. The company's geographic segments are: the United States, Asia, Mexico, Europe, the Middle East, Africa and India.

TRACON Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of targeted therapeutics for cancer and wet age-related macular degeneration. The company is developing its primary product candidate, TRC105 (carotuximab), an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or in combination with inhibitors of the programmed cell death protein 1 pathway. The company's second clinical stage product oncology candidate is TRC102, a small molecule being developed for the treatment of lung cancer and mesothelioma.